Unique ID issued by UMIN | UMIN000028523 |
---|---|
Receipt number | R000032643 |
Scientific Title | Identification of genetic markers that predicts adverse effects of new melanoma therapies |
Date of disclosure of the study information | 2017/09/01 |
Last modified on | 2019/08/06 08:36:30 |
Identification of genetic markers that predicts adverse effects of new melanoma therapies
Identification of genetic markers that predicts adverse effects of new melanoma therapies
Identification of genetic markers that predicts adverse effects of new melanoma therapies
Identification of genetic markers that predicts adverse effects of new melanoma therapies
Japan |
malignant melanoma
Dermatology |
Malignancy
YES
To identify HLA and KIR alleles that correlate with adverse effect of melanoma new therapy
Others
Pharmacogenetics
Adverse effect that result from new melanoma therapy
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Patients who are treated with systemic therapies
Patients who are followed for less than 3 months after the initiation of the therapy
100
1st name | Atsushi |
Middle name | |
Last name | Otsuka |
Kyoto University
Dermatology
606-8507
54 Kawahara-cho Shogoin Sakyo-ku Kyoto-shi 606-8507 Japan
075-751-3310
otsukamn@kuhp.kyoto-u.ac.jp
1st name | Chisa |
Middle name | |
Last name | Nakashima |
Kyoto University
Dermatology
606-8507
54 Kawahara-cho Shogoin Sakyo-ku Kyoto-shi 606-8507 Japan
075-751-33310
chisa313@kuhp.kyoto-u.ac.jp
Kyoto University
Ono Pharmaceutical Co., Ltd. Bristol-Myers Squibb K.K.
Profit organization
Kyoto University
54 Kawahara-cho Shogoin Sakyo-ku Kyoto-shi
075-753-4680
ethcom@kuhp.kyoto-u.ac.jp
NO
2017 | Year | 09 | Month | 01 | Day |
Published
112
Our analysis showed that no KIR gene was associated with a response to nivolumab. The KIR/KIR-ligand combination did not correlate with a response to nivolumab. KIR genes were not predictive of experiencing adverse events of grade 2 or greater. We conclude that the KIR genotype or KIR/KIR-ligand genotype do not show predictive value in melanoma patients receiving nivolumab.
2019 | Year | 08 | Month | 06 | Day |
none
Completed
2017 | Year | 12 | Month | 01 | Day |
2017 | Year | 10 | Month | 23 | Day |
2017 | Year | 12 | Month | 01 | Day |
2018 | Year | 12 | Month | 28 | Day |
To identify HLA alleles that correlate with adverse effect of new melanoma therapy
2017 | Year | 08 | Month | 03 | Day |
2019 | Year | 08 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032643
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |